To determine the impact of paroxysmal atrial fibrillation on quality of life and to determine the predictors of quality of life, particularly the role of symptomatology and autonomic function.
Introduction
Atrial fibrillation is a very common arrhythmia, and its prevalence is still increasing [1] . In recent years, numerous studies have attested to the impact of atrial fibrillation on life expectancy, haemodynamics, left ventricular function, risk of thrombo-embolism, and on atrial electrophysiology, histology and molecular biology. In contrast, a paucity of data exists about its impact on quality of life [2, 3] . Several studies have reported on the beneficial effect of His bundle ablation on quality of life in patients with medically refractory atrial fibrillation [4] [5] [6] . However, generally findings were not compared with those of subjects without atrial fibrillation and sample-sizes were small. Moreover, these patients represent an extreme part of the spectrum since they were highly symptomatic. We therefore conducted a quality of life study in a sizeable group of patients with paroxysmal atrial fibrillation, using a large control group. The first aim of the study was to determine the impact of paroxysmal atrial fibrillation on quality of life. The second aim was to determine which factors within the group of atrial fibrillation patients are independent predictors of quality of life. In addition to clinical characteristics, medication and arrhythmia burden, we considered the role of symptomatology and autonomic nervous system function. We hypothesized that severe symptoms would be associated with low quality of life. Further, since autonomic function presumably plays an important role in mitigating the potentially adverse haemodynamic effects of atrial fibrillation, impaired autonomic function also was hypothesized to be associated with low quality of life.
Methods

Patient selection and definitions
Consecutive patients presenting at the out-patient clinic with paroxysmal atrial fibrillation, aged >18 years, were considered eligible for the study. Paroxysmal atrial fibrillation was defined as recently proposed by Gallagher and Camm [7] : paroxysms had to terminate either spontaneously or after treatment with an antiarrhythmic drug. Patients with significant extracardiac or systemic disease were excluded to prevent interference with assessment of quality of life [18] . Patients with diabetes mellitus and autonomic neuropathy were also excluded. Lone atrial fibrillation was inferred when routine cardiac investigations (echocardiogram, ergometry) did not reveal structural heart disease. Patients with hypertension were considered to have structural heart disease. Vagal atrial fibrillation was presumed present in cases in which atrial fibrillation occurred predominantly at rest or during sleep, preceded by heart rate slowing as documented by Holter monitoring (if available). The frequency and duration of paroxysms of atrial fibrillation were based on the patient's own assessment. Although the concept of quality of life is inherently subjective and no universal definition exists, there is consensus that quality of life should be assessed on the basis of several components, including physical condition, psychological well-being, social activities and everyday activity [2, 3] . Thus, quality of life can be taken as a multidimensional concept that is best approached through a multi-attribute measurement technique. Patients who agreed to participate in the study underwent additional investigations consisting of questionnaires, Holter monitoring and autonomic function testing. Cardioactive medication was stopped at least five half-lives prior to testing if deemed acceptable by the attending physician. Sotalol was categorized as both a class III antiarrhythmic and a beta-blocker. The study was approved by the institutional ethics committee and informed consent was obtained from all patients.
Quality of life
Quality of life was measured by the SF-36 (Medical Outcomes Study Short-Form Health Survey [9, 10] ). The SF-36 is a widely used and thoroughly validated, standardized, generic health survey, consisting of eight subscales that measure physical functioning, bodily pain, role limitations due to physical or emotional problems, social role functions, as well as sense of vitality and of mental and general health. Scores of each subscale are normalized to a scale ranging from 0 to 100, with lower scores representing a lower quality of life. The SF-36 was developed to exclude potential bias due to age and gender. Patients were asked to complete the questionnaire and then return it by mail. Since this was not a longitudinal study, nor did we assess any treatment effect, we did not incorporate any disease-specific questions.
Holter monitoring
Twenty-four-hour ambulatory electrocardiographic monitoring (Holter-monitoring) was performed using a three-channel Marquette Holter recorder (series 8500). The recordings were processed by an experienced analyst using a Marquette Holter system (Marquette Laser Holter Systems, series 8000XP). We analysed heart rate variability using Marquette software (version 002A), in accordance with recommendations from the Task Force of the European Society of Cardiology and North American Society of Pacing and Electrophysiology [11] . Recordings with >5% noise or ectopic beats, including atrial fibrillation, were excluded from analysis. In cases of atrial fibrillation, the tapes were used to gain an impression of the ventricular rate response. The following time-domain parameters were calculated: the standard deviation of all normal-to-normal RR-intervals during 24 h (SDNN) and the root mean square of successive differences between normal RR-intervals (rMSSD). The first parameter reflects overall heart rate variability and represents vagal as well as sympathetic function, whereas the latter parameter is more specific for vagal function. Discrete Fourier transformation was used for the analysis of the frequency (spectral) domain parameters. The following parameters were calculated: low-frequency power (0·04-0·15 Hz), high-frequency power (0·15-0·40 Hz), and total power (0·0033-0·40 Hz). High frequency power reflects vagal function, whereas low frequency power is taken to represent combined vagal and sympathetic function.
Autonomic function testing
A battery of four tests was performed: deep breathing, isometric handgrip, standing up and head-up tilting. Methods for these have been described recently [12] . Briefly, tests were performed in the morning after fitting the Holter recorder. Blood pressure and heart rate were measured continuously (beat-to-beat) with the Finapress system with a cuff around the middle finger of the right hand [13] . During the tests the patient was lying on a bed, which could be tilted to an 80 upright position. After signal stabilization a 10-min baseline recording was taken. A stabilization period of 5 min was allowed after each manoeuvre. The data were digitized and stored in a personal computer for subsequent analysis. Although most tests influence vagal and sympathetic function simultaneously, the extent to which each part of the autonomic nervous system is activated is variable [14] . Deep breathing is considered mainly a test of vagal function, whereas isometric handgrip is used to test sympathetic function. Standing up and head-up tilting reflect both vagal and sympathetic function. Baseline data were used to calculate baroreflex sensitivity (see below).
Deep breathing Using a metronome, the patient was instructed to breathe deeply in and out six times during 1 min. The mean of all six breaths was taken to calculate the ratio between in-and expiratory heart rate.
Isometric handgrip During 3 min a handgrip was held at 30% of the previously established maximum force in the hand contralateral to the hand used for the Finapress. The maximal increase in diastolic blood pressure was determined.
Standing up
The patient was asked to stand up from the bed. The 30-15 ratio was calculated as the ratio between the highest heart rate after standing up (usually around the 15th beat) and the lowest heart rate (usually around the 30th beat).
Head-up tilting
The bed on which the patient was positioned was tilted to the 80 upright position. Tilting was continued for 30 min or terminated earlier in case of symptoms (pre-syncope). A positive response was defined as a sudden drop in systolic blood pressure >30 mmHg (with or without concomitant bradycardia) accompanied by symptoms.
Baroreflex sensitivity
The baseline blood pressure and heart rate data were used for non-invasive determination of baroreflex sensitivity, according to the method by Robbe et al. [15, 16] . First, the baseline recording was plotted to select the longest portion of signals free from artifacts or large transients having a minimal length of 4·5 min. Then, by performing cross-spectral analysis between the blood pressure and heart rate time series the coherence function and the transfer function modulus were computed. The mean value of the transfer function modulus in the frequency band 0·07 to 0·14 Hz, considering only those points where coherence was >0·3, was taken as the measure of baroreflex-sensitivity.
Symptomatology
To examine the influence of symptoms during the paroxysms of atrial fibrillation on quality of life, the patient was asked at entry into the study to quantify these symptoms according to severity. Given our focus on autonomic function we asked the patient to consider the following symptoms, some of which supposedly reflect some degree of adrenergic activation (particularly the last three items): palpitations, dizziness, chest pain, perspiration, coldness and anxiety. Symptoms were scored on a five-point scale, ranging from 1 to 5: 1=none, 2=light, 3=mild, 4=moderate, 5=severe.
Data analysis
Mean values the standard deviation were calculated for normally distributed variables, whereas median values with range were used for non-normal distributions. In order to determine the relative quality of life of the patients, scores in each of the eight subscales of the SF-36 were compared with scores in a previously established control group using Student's t-test. The control group consisted of a pre-defined stratum of 180 persons, age 45-55 years, taken from a random population sample of 1063 healthy adults [17] . In order to identify the predictors of quality of life, univariate analysis was performed on the separate SF-36 subscales with particularly low scores. Studied variables comprised clinical characteristics as well as data obtained during the additional investigations. To limit the number variables we made a selection, focusing the hypothesis, i.e. the importance of symptomatology and autonomic function. The analysis was performed using the proportional odds model for ordered categorical data [18] . To examine linearity, continuous variables were divided into quartiles (or quintiles in case of the symptoms during the paroxysms). If the quartiles showed a linear relation with quality of life the variable was taken in the model as continuous. If a non-linear relation was apparent, quartiles were combined and the variable was included in the model as a dichotomous variable. Variables with a univariate P value <0·1 were selected for multivariate regression analysis. Using backward selection, a model was constructed to identify the independent predictors of quality of life. P values <0·05 were considered statistically significant. All statistical analyses were carried out using the Statistical Analysis System (SAS) programme, version 6·12.
Results
Patient characteristics
The study group comprised 73 patients. Clinical characteristics are given in Table 1 . Most patients were male and no structural heart disease was apparent in the majority (lone atrial fibrillation). None of the patients had congestive heart failure. Mean echo-parameters were within the normal range. Arrhythmia burden in terms of total duration, frequency of paroxysms and duration of paroxysms varied considerably. On average, patients had a 3-year history of one paroxysm per week lasting 2 h. Vagal atrial fibrillation was observed in
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one-third of the patients. Most patients (77%) used medication to suppress their arrhythmia or control ventricular rate during atrial fibrillation. Medication was stopped prior to the additional investigations in nine patients, leaving 47 patients on medication.
Quality of life
All patients completed the SF-36 questionnaire in full. Scores are given in Table 2 . When compared with the age-matched control group, patients with atrial fibrillation had statistically significantly lower scores on all SF-36 subscales, with the exception of the pain subscale. Scores in four subscales were markedly lower (P<0·001): physical role function, emotional role function, vitality and general health.
Holter monitoring
All recordings were technically adequate. However, in 20 recordings >5% ectopy was present due to paroxysms of atrial fibrillation, precluding further analysis; the mean ventricular rate during the atrial fibrillation in these patients was 99 16 beats . min 1 . Results from the remaining 53 patients are listed in Table 3 . All mean heart rate variability parameters were below normal values, though to a varying degree.
Autonomic function testing
In threepatients autonomic function testing was not feasible due to atrial fibrillation, including a patient in whom atrial fibrillation was elicited by standing up. Results from the remaining 70 patients are listed in Table 3 . Mean responses to isometric handgrip and standing up were normal, whereas the response to deep breathing was marginally depressed. Head-up tilting caused hypotension in 19 patients, which was associated with symptoms in nine patients. Coherence was >0·3 in all patients, allowing reliable calculation of the modulus, that is, baroreflex-sensitivity. Mean baroreflexsensitivity was below the normal value.
Symptomatology
Scores on symptoms during paroxysms were as follows: palpitations 4·2 1·4; dizziness 3·4 1·6; chest pain 2·5 2·0; perspiration 2·7 1·7; coldness 2·6 1·6; and anxiety 3·0 1·6.
Predictors of quality of life
Based on the high statistical significance we chose the following four subscales for the analysis of the independent predictors of quality of life: physical role function, emotional role function, vitality and general health. Results are given in Table 4 . High baroreflex sensitivity and low frequency of paroxysms (1st quartile: <0·25 per week) were associated with preserved physical role function, whereas moderate to severe dizziness and chest pain during paroxysms (4th and 5th quintile) were asssociated with impaired physical role function. Emotional role function was preserved in cases of high total power (4th quartile) and impaired in cases of severe perspiration (5th quintile). Vitality was low in cases of beta-blocker use and poor response to deep breathing (1st quartile), and preserved in patients with vagal atrial fibrillation. Finally, general health was poor in cases of moderate to severe perspiration (4th and 5th quintile) and good in cases of a high 30-15 ratio (4th quartile).
Discussion
This study shows that paroxysmal atrial fibrillation causes significant impairment of the quality of life as measured by the SF-36, even in the absence of structural heart disease. In particular, physical role function, emotional role function, vitality and general health appear to be impaired. The results also indicate that symptomatology and autonomic function are independent predictors of quality of life in patients with paroxysmal atrial fibrillation.
There is an increasing awareness that quality of life is important and quality of life has become a major end-point in clinical trials. However, despite the fact that atrial fibrillation is a very common disorder with profound impact in terms of morbidity and mortality, data on the quality of life in patients with atrial fibrillation are sparse. Overviews on this issue have recently been published [2, 3] , stressing the need for controlled, largevolume studies in representative patients. In fact, several studies are ongoing including an international study (International Study on Quality of Life in Atrial Fibrillation) which focuses on the effect of atrial fibrillation on quality of life over time. The first results indicate that atrial fibrillation is associated with impaired quality of life, as measured by the SF-36, and that no significant changes occur over time (12 months) [19] . Quality of life was impaired irrespective of arrhythmia burden (frequency and duration of paroxysms), type of atrial fibrillation (paroxysmal, persistent or permanent) and other indices of illness (New York Heart Association functional class, left ventricular ejection fraction) [20, 21] . Quality of life was as impaired as in coronary artery disease patients who had recently had angioplasty, and perceived 'illness burden' was comparable to that of renal failure patients on dialysis [20] . We here present the first full report on a controlled, large-volume study on quality of life in patients with paroxysmal atrial fibrillation. The study group consisted of 73 patients, the majority of whom had no structural heart disease. On average, patients had a 3-year-history of one paroxysm per week lasting 2 h. The results support the finding cited above [19] in that paroxysmal atrial fibrillation was found to be associated with impaired quality of life, as measured by the SF-36. Scores were statistically significantly lower compared with the controls in as many as seven of the eight SF-36 subscales, being particularly low with respect to physical role function, emotional 
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role function, vitality and general health. Comparison of this type of data from different studies in patients with different disorders is inherently difficult, particularly since the SF-36 lacks a composite score. Nevertheless, it seems that patients with life-threatening ventricular arrhythmias do have a lower quality of life, though it should be realized that severe underlying heart disease is often present in these patients and may be presumed to account to a large extent for the low quality of life [22] . However, the effect of angina pectoris on quality of life would appear to be comparable with our findings [23] . This study also sought to determine which factors within the group of atrial fibrillation patients are independent predictors of quality of life. We considered clinical characteristics, medication and arrhythmia burden. In addition, we argued that autonomic function and symptomatology might have an impact. The role of the autonomic nervous system in atrial fibrillation is complex. On the one hand, autonomic factors play a role in the genesis of atrial fibrillation [24] [25] [26] , particularly vagal activity (vagal atrial fibrillation). On the other hand, atrial fibrillation may affect autonomic function through its potential effect on haemodynamics [27] . In particular, arterial baroreflex activation may occur in the setting of acute atrial fibrillation so as to ensure haemodynamic homeostasis. In other words, intact autonomic function is presumably needed to mitigate the potentially adverse haemodynamic effect of atrial fibrillation, analogous to its role in the setting of ventricular tachyarrhythmias [28, 29] . However, the relationship between the clinical history (of vagal arrhythmia) and autonomic function is far from straightforward: some patients with vagal atrial fibrillation experience intense adrenergic activation whereas no such response is clinically apparent in others. Finally, atrial fibrillation may elicit a vasovagal response in susceptible patients [30] . Symptomatology varies appreciably among patients with atrial fibrillation, some patients reporting severe symptoms whereas others are virtually asymptomatic despite substantial arrhythmia burden [31, 32] . Moreover, some symptoms may be more disruptive than others. We hypothesized that these differences have a bearing on quality of life. The results seem to support previous data [20, 21] that neither structural heart disease nor arrhythmia burden have an independent impact on quality of life in patients with atrial fibrillation (with the exception of frequency of paroxysms). In contrast, our hypothesis that both autonomic function and symptomatology were independently related to quality of life was confirmed. In all four studied subscales autonomic variables emerged as significant predictors. Taken together, depressed autonomic function, particularly vagal function, was predictive of impaired quality of life function. However, caution is necessary, since the data do not prove a causal relation. Previous studies have shown that affective disorders (including depression) may cause impairment of autonomic function [33, 34] , so that low quality of life (of whatever cause) might have been the initial problem in our patients, with impaired autonomic function and paroxysmal atrial fibrillation as secondary phenomena. It is clear that a positive response to head-up tilting was not predictive of impaired quality of life. However, the observed high prevalence (12%) is intriguing as such and of potential interest with respect to the genesis of atrial fibrillation [25] . In addition to autonomic function, symptomatology played a role. As expected, scores on palpitations were highest, but palpitations were not predictive of impaired quality of life. Rather, the secondary symptoms of dizziness, chest pain and perspiration were predictive of low quality of life. Though a causal relation is again hard to establish, it thus appears that the impact of symptoms extends beyond the actual paroxysms of the arrhythmia. Possibly, anticipation of disruptive symptoms has a depressant effect on quality of life. The importance of symptomatology is supported by the recent findings that asymptomatic atrial fibrillation does not significantly deteriorate quality of life [35] and that quality of life improves following medical treatment of atrial fibrillation [36] . The majority of patients were on medication during Holter monitoring and autonomic function testing, which may have influenced the results. However, the different classes of drugs did not emerge as independent predictors of quality of life in the multivariate analysis, with the exception of beta-blockers. Also, exclusion of 20 Holter recordings from further analysis because of >5% ectopy might have introduced a selection bias. Finally, since our institute is a tertiary referral centre, the patient group may not be entirely representative of clinical practice. Because of a referral effect, the quality of life in our patients with atrial fibrillation may be lower than in patients in a primary care setting. Further selection occurred due to exclusion of patients with extracardiac or systemic disease. This is probably reflected by the high proportion of patients with lone atrial fibrillation and vagal atrial fibrillation. However, given the fact that on average patients were relatively 'healthy', their low quality of life is even more striking.
The available data unequivocally show that quality of life is impaired in patients with atrial fibrillation. Quality of life should therefore be added as a target for therapeutic intervention. Though there is much yet to learn, the present study provides insight into the potential causes of impaired quality of life, with symptomatology and autonomic function playing an important role. Apparently, the autonomic nervous system is not only implicated in the genesis of atrial fibrillation, but also in its consequences, including the way in which the arrhythmia is experienced.
